** Shares of drug developer Passage Bio PASG.O fall 12% to 38 cents premarket
** Co says it is doing a 1-for-20 reverse stock split, effective July 14, 2025
** For every 20 shares, shareholders will now have 1 share, co says
** The number of outstanding shares will drop from about 62.4 million to about 3.1 million and the stock will keep trading under the symbol 'PASG', Passage Bio says
** PASG is currently developing gene therapies for rare, inherited neurodegenerative diseases, The company's programs focus mainly on treating disorders that affect the central nervous system
** As of last close, PASG stock down 22.2% YTD
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com))
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。